Tvardi Selects Ulcerative Colitis as Lead Indication for STAT3 Inhibitor TTI-109
TVRD sits 38% above its 52-week low of $1.5 on light trading volume (0.3× avg).
Summary
Tvardi Therapeutics has selected ulcerative colitis as the first disease target for its oral STAT3 inhibitor TTI-109, supported by new Phase 1 data showing immune cell modulation. A clinical trial is planned for 2027, contingent on funding and regulatory clearance.
Key Events · Product Development and Regulatory · TVRD
-
UC Selected as Lead Indication
Tvardi chose ulcerative colitis as the initial indication for TTI-109, a STAT3 inhibitor, targeting a $3B U.S. market with high unmet need.
-
Phase 1 Data Support Decision
In a healthy volunteer study, TTI-109 reduced pathogenic Th17 cells by up to 76%, Tfh cells by up to 43%, and B cells by up to 71%, all implicated in UC.
-
Trial Planned for 2027, Funding Needed
A Phase 2 trial in moderate-to-severe UC is planned for 2027, but is subject to IND clearance and additional funding — a key risk given the company's going-concern status.
-
KOL Webinar on August 19
Management will host a KOL event with Dr. Randy Longman on August 19, 2026, to present new data and discuss the UC treatment landscape.
Analysis · TVRD · Life Sciences
Tvardi is advancing its next-generation STAT3 inhibitor TTI-109 into ulcerative colitis, a $3 billion U.S. market where over 70% of patients fail existing therapies. The decision is backed by Phase 1 data showing TTI-109 reduced key immune cell populations implicated in UC pathology — Th17, Tfh, and B cells — by up to 76%. The company plans a 2027 clinical trial, but initiation depends on IND clearance and securing additional funding, a critical caveat given the company's going-concern warning and recent ATM usage. The announcement also includes a KOL webinar on August 19, 2026, to discuss the data and UC landscape.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TVRD was trading at $2.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.1M. The 52-week trading range was $1.50 to $43.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.